LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical System’s industry-leading cancer fighting technology is coming to the prestigious Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. A MEVION S250 proton therapy system is being purchased by Swiss-based Innovative Care SA (IC) and will be installed at the CHUV through a public-private partnership. It is the first announced sale of a MEVION S250 in Europe.
“Innovative Care SA is proud to partner with the CHUV to bring advanced proton therapy to Switzerland,” said Michel Racheter, CEO of Innovative Care SA. “Since 2009, we undertook a rigorous yearly international search for the best proton therapy partner and determined the quality and value of the Mevion system is unique. Mevion’s low capital, operating and energy costs, combined with its repeatedly proven fast ramp-up and high throughput, make the MEVION S250 the ideal system to complement the CHUV’s state-of-the-art medical and technical platform.”
“This strategic public-private partnership for several decades with IC gives our patients access to Mevion’s proton therapy and highly contributes to the development of the CHUV as a major cancer center in Europe,” said Philipp Müller, chief financial officer at the CHUV.
The MEVION S250 at the CHUV will be based in the French-speaking region of Switzerland providing convenient access to this leading-edge treatment for patients in Switzerland and beyond. Construction will begin the first quarter of 2016 and the first patient will be treated in 2017.
“Mevion has consistently demonstrated the flexibility, resources and ability to work under all types of financing and partnership arrangements,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems. “Because of the quality and value of the MEVION S250, it is the system of choice for cancer centers ranging from large academic medical centers to a private, physician-owned practice. We are pleased to add the CHUV to the list of highly regarded institutions that will offer their patients the benefits of treatment on a Mevion system.”
Three Mevion systems are treating patients in the United States and four more are under installation. In August, Mevion announced a significant international expansion that included a round of private financing worth up to US$200 million and the formation of a joint venture in China. The investment will fund an increase in Mevion’s manufacturing capacity and global service capability to support the installation of new proton therapy sites in the U.S., China and Europe.
To learn more about Mevion, please visit booth 650 at the 57th annual meeting of the American Society for Radiation Oncology (ASTRO), held October 18 – 21 in San Antonio, Texas.
About Mevion Medical Systems
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers.
Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan and a joint venture in China. For more information, please visit www.mevion.com.
About Innovative Care SA (IC)
Innovative Care SA is a Swiss privately held company based in Nyon, Switzerland dedicated to the development of turnkey cancer facilities for leading private and public institutions.
Innovative Care SA board of Directors is composed of Michel Racheter, Chief Executive Officer (CEO); Volker Kirchner, Chief Medical Officer (CMO) and Jean-Luc Herbez, Head Legal.